Pharos IBio Co Ltd

388870

Company Profile

  • Business description

    Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

  • Contact

    427beon-gil, Dongan-gu
    1407 and 1408, 38, Heungan-daero, Seongji Star With
    Gyeonggi-do, Gwanyang-dong
    Anyang-si
    KOR

    T: +82 313456170

    https://www.pharosibio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    34

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,507.902.80-0.03%
CAC 407,873.8323.730.30%
DAX 4023,638.5672.020.31%
Dow JONES (US)42,140.43269.67-0.64%
FTSE 1008,602.922.06-0.02%
HKSE23,438.11329.841.43%
NASDAQ19,010.09301.741.61%
Nikkei 22537,971.75211.51-0.55%
NZX 50 Index12,783.133.61-0.03%
S&P 5005,886.5542.360.72%
S&P/ASX 2008,263.505.50-0.07%
SSE Composite Index3,381.176.300.19%

Market Movers